Comtan is a drug owned by Orion Pharma. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 14, 2018. Details of Comtan's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6599530 | Oral compacted composition comprising catechol derivatives |
Sep, 2018
(6 years ago) |
Expired
|
| US5446194 | Pharmacologically active catechol derivatives |
Oct, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Comtan is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Comtan's family patents as well as insights into ongoing legal events on those patents.
Comtan's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Comtan's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 14, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Comtan Generic API suppliers:
Entacapone is the generic name for the brand Comtan. 8 different companies have already filed for the generic of Comtan, with Ajanta Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Comtan's generic
How can I launch a generic of Comtan before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Comtan's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Comtan's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Comtan -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 200 mg | 11 Apr, 2007 | 1 | 16 Aug, 2012 | 14 Sep, 2018 | Extinguished |
Alternative Brands for Comtan
Comtan which is used for treating Parkinson's disease., has several other brand drugs in the same treatment category and using the same active ingredient (Entacapone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch |
| |||||||||||||
| Boehringer Ingelheim |
| |||||||||||||
| Impax |
| |||||||||||||
| Orion Pharma |
| |||||||||||||
| Supernus Pharms |
| |||||||||||||
| Teva |
| |||||||||||||
Apart from brand drugs containing the same ingredient, some generics have also been filed for Entacapone, Comtan's active ingredient. Check the complete list of approved generic manufacturers for Comtan
About Comtan
Comtan is a drug owned by Orion Pharma. It is used for treating Parkinson's disease. Comtan uses Entacapone as an active ingredient. Comtan was launched by Orion Pharma in 1999.
Approval Date:
Comtan was approved by FDA for market use on 19 October, 1999.
Active Ingredient:
Comtan uses Entacapone as the active ingredient. Check out other Drugs and Companies using Entacapone ingredient
Treatment:
Comtan is used for treating Parkinson's disease.
Dosage:
Comtan is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 200MG | TABLET | Prescription | ORAL |